Abstract MP66: Cheese Consumption and Blood Lipids; a Systematic Review and Meta-analysis of Randomized Controlled Trials

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Janette de Goede ◽  
Johanna M Geleijnse ◽  
Eric L Ding ◽  
Sabita S. Soedamah-Muthu
Keyword(s):  
Total Cholesterol ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Fat Content ◽  
Control Treatment ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Lipids And Lipoproteins

Aims: Cheese may have a different effect on lipids and lipoproteins than expected from the saturated fat content. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to examine the effect of cheese consumption on blood lipids and lipoproteins in healthy populations. Methods: A systematic search in MEDLINE, EMBASE, Scopus, Cababstracts, Cochrane Controlled Trials Register, Clinicaltrials.gov was performed to identify RCTs of cheese supplementation in human adults with total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides as a primary or secondary outcome (published until September 2013). A quantitative meta-analysis was performed if more than four RCTs with a comparable control treatment were available. Within person-differences of lipids with corresponding standard errors caused by the cheese compared to the control treatment were pooled (random effects model, STATA 11.0). Results: We identified 15 RCTs, published between 1978 and 2012. We pooled four RCTs comparing the effect of cheese intake to butter with a similar fat content on plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides. The amount of cheese used in these trials was rather large, ranging between 120 and 205 g/d. This is approximately equivalent to 3 to 5 cheese servings per day. Intake of cheese (weighted mean difference: 142.6 g/d) reduced total cholesterol significantly by -0.27 mmol/l (95% CI: -0.36 to -0.18), LDL-C by -0.21 mmol/l (95% CI: -0.29 to -0.13), and HDL-C by -0.05 (95% CI: -0.08 to -0.02) compared to butter. The pooled effect on triglycerides was 0.004 (95% CI: -0.058 to 0.065). No heterogeneity was observed (all I 2 =0%). Cheese was also compared with tofu (n=4 RCTs), fat-modified cheese (n=3), CLA-rich cheese (n=3), milk (n=2), fish (n=1), egg white (n=1). Trials that compared cheese with tofu or fat-modified cheese suggest that differential effects of the products can mainly be attributed to the differences in fatty acid content of the diets. Comparisons with CLA-rich cheese were of limited value because those studied the effects of CLA (and not cheese). Too few trials with milk, egg white, and fish were available to draw conclusions. Conclusions: Based on a limited number of trials, cheese appears less hypercholesterolemic than butter with a similar fat content. Differences in plasma lipids based on cheese compared with tofu and fat-modified products are likely to be caused by the different fat content of the total diets.

scholarly journals A Systematic Review and Meta-analysis of Randomized Controlled Trials on the Effects of Turmeric and Curcuminoids on Blood Lipids in Adults with Metabolic Diseases

2019 ◽  
Vol 10 (5) ◽  
pp. 791-802 ◽  
Author(s):  
Fen Yuan ◽  
Hui Dong ◽  
Jing Gong ◽  
Dingkun Wang ◽  
Meilin Hu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Metabolic Diseases ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled

ABSTRACT Dyslipidemia is a global health problem and a high risk factor for atherosclerosis, which can lead to serious cardiovascular disease (CVD). Existing studies have shown inconsistent effects of turmeric and curcuminoids on blood lipids in adults. We performed this systematic review and meta-analysis to evaluate the effects of turmeric and curcuminoids on blood triglycerides (TG), total cholesterol (TC), LDL cholesterol, and HDL cholesterol. We searched the English databases of the Web of Science, PubMed, Ovid (including EMBASE and MEDLINE), Scopus, and the Cochrane Library and 2 Chinese databases, Wanfang Data and China National Knowledge Infrastructure, for randomized controlled trials (RCTs) that studied the effects of turmeric and curcuminoids on blood TG, TC, LDL cholesterol, and HDL cholesterol in subjects with metabolic diseases. With random-effects models, separate meta-analyses were conducted by using inverse-variance. The results are presented as the mean difference with 95% CIs. Evidence from 12 RCTs for TG, 14 RCTs for TC, 13 RCTs for LDL cholesterol, and 16 RCTs for HDL cholesterol showed that turmeric and curcuminoids could lower blood TG by −19.1 mg/dL (95% CI: −31.7, −6.46 mg/dL; P = 0.003), TC by −11.4 mg/dL (95% CI: −17.1, −5.74 mg/dL; P < 0.0001), and LDL cholesterol by −9.83 mg/dL (95% CI: −15.9, −3.74 mg/dL; P = 0.002), and increase HDL cholesterol by 1.9 mg/dL (95% CI: 0.31, 3.49 mg/dL; P = 0.02). In conclusion, turmeric and curcuminoids can significantly modulate blood lipids in adults with metabolic diseases. However, these findings should be interpreted cautiously because of the significant heterogeneity between included studies (I2 > 50%). There is a need for further RCTs in future.

scholarly journals Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials

2018 ◽  
Vol 108 (5) ◽  
pp. 922-932 ◽  
Author(s):  
Elena Jovanovski ◽  
Shahen Yashpal ◽  
Allison Komishon ◽  
Andreea Zurbau ◽  
Sonia Blanco Mejia ◽  
...  
Keyword(s):  
Randomized Controlled Trials ◽  
Apolipoprotein B ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Cvd Risk ◽  
Randomized Controlled ◽  
Evaluation Approach

ABSTRACT Background Studies have identified viscous dietary fiber as potentially attenuating cholesterol, including psyllium, which reduces LDL cholesterol and thus may complement cardiovascular disease (CVD) treatment. Objectives The aims of this study were to update evidence on the effect of psyllium on LDL cholesterol and to provide an assessment of its impact on alternate markers: non-HDL cholesterol and apolipoprotein B (apoB). Design Medline, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials were searched through 3 October 2017. Independent reviewers extracted relevant data and assessed risk of bias. We included randomized controlled trials with a duration of ≥3 wk that assessed the effect of psyllium on blood lipids in individuals with or without hypercholesterolemia. Data were pooled by using the generic inverse variance method with random-effects models and expressed as mean differences (MDs) with 95% CIs. Heterogeneity was assessed by Cochran's Q statistic and quantified by the I2 statistic. Overall quality of the evidence was assessed by using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Results We included 28 trials in our analysis (n = 1924). Supplementation of a median dose of ∼10.2 g psyllium significantly reduced LDL cholesterol (MD = –0.33 mmol/L; 95% CI: –0.38, –0.27 mmol/L; P < 0.00001), non-HDL cholesterol (MD = –0.39 mmol/L; 95% CI: –0.50, –0.27 mmol/L; P < 0.00001), and apoB (MD = –0.05 g/L; 95% CI: –0.08, –0.03 g/L; P < 0.0001). Effect estimates for LDL cholesterol and non-HDL cholesterol were graded as moderate quality on the basis of downgrades for inconsistency and graded as high quality for apoB. Conclusion Psyllium fiber effectively improves conventional and alternative lipids markers, potentially delaying the process of atherosclerosis-associated CVD risk in those with or without hypercholesterolemia. This trial is registered at www.clinicaltrials.gov as NCT03346733.

The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials

2018 ◽  
Vol 24 (27) ◽  
pp. 3184-3199 ◽  
Author(s):  
Reza Tabrizi ◽  
Sina Vakili ◽  
Kamran B. Lankarani ◽  
Maryam Akbari ◽  
Naghmeh Mirhosseini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Metabolic Syndrome ◽  
Glycemic Control ◽  
Total Cholesterol ◽  
Fasting Glucose ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Cholesterol Levels

Background: This systematic review and meta-analysis of randomized controlled trials (RCTs), were performed to determine the effects of curcumin intake on glycemic control and lipid profiles among patients with metabolic syndrome (MetS) and related disorders. Methods: We searched the following databases up until January 2018: MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. The relevant data were extracted and evaluated for quality of the studies in accordance with the Cochrane risk of bias tool. Data were pooled using the inverse variance method and expressed as standardized mean difference (MDs) with 95% confidence intervals (95% CI). Results: Twenty-six trials with 1890 participants were included in the current meta-analysis. The findings demonstrated the significant association between curcumin intake and reduced fasting glucose levels (SMD -0.78; 95% CI, -1.20, -0.37; P<0.001), homeostasis model of assessment-estimated insulin resistance (SMD -0.91; 95% CI, -1.52, -0.31; P=0.003) and HbA1c (SMD -0.92; 95% CI, -1.37, -0.47; P<0.001). In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01). However, curcumin intake significantly increased insulin levels (SMD 0.92; 95% CI, 0.06, 1.78; P=0.036). We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels (SMD 0.28; 95% CI, -0.22, 0.77; P=0.27). Conclusion: Overall, curcumin consumption was associated with a significant reduction in fasting glucose, HOMA-IR, HbA1c, triglycerides and total cholesterol levels among patients with MetS and related disorders, but did not affect LDL- and HDL-cholesterol levels.

The Effects of Vitamin D Supplementation on Glucose Metabolism and Lipid Profiles in Patients with Gestational Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2017 ◽  
Vol 49 (09) ◽  
pp. 647-653 ◽  
Author(s):  
Maryam Akbari ◽  
Mahmood Mosazadeh ◽  
Kamran Lankarani ◽  
Reza Tabrizi ◽  
Mansooreh Samimi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Vitamin D ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Vitamin D Supplementation ◽  
Controlled Trials ◽  
Model Assessment ◽  
Randomized Controlled ◽  
Cholesterol Levels

AbstractThis systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to summarize the effect of vitamin D supplementation on glucose homeostasis parameters and lipid profiles in gestational diabetes (GDM) patients. We conducted an electronic systematic search of MEDLINE, and 4 other research databases from inception to August 2016, in addition to performing hand searches and consulting with experts in the field. The index of heterogeneity between studies was determined using Cochran (Q) and I-squared tests. Given the existing heterogeneity between studies, a fix or random effect model was performed to estimate the standardized mean difference (SMD) for each variable by using inverse variance method and Cohen statistics. Six randomized clinical trials (187 subjects and 184 controls) were included. The results showed that vitamin D supplementation significantly reduced the homeostasis model assessment of insulin resistance (HOMA-IR) [SMD −0.66; 95% confidence interval (CI), −1.14 to −0.18], homeostatic model assessment-B cell function (HOMA-B) (SMD −0.52; 95% CI, −0.79 to −0.25), LDL-cholesterol levels (SMD −0.33; 95% CI, −0.58 to −0.07), and significantly increased quantitative insulin sensitivity check index (QUICKI) (SMD 0.73; 95% CI, 0.26 to 1.20). We found no beneficial effect of vitamin D supplementation on fasting plasma glucose (FPG), insulin, HbA1c, total-, HDL-cholesterol, and triglycerides concentrations. In conclusion, this meta-analysis demonstrated that vitamin D supplementation may lead to an improvement in HOMA-IR, QUICKI, and LDL-cholesterol levels, but did not affect FPG, insulin, HbA1c, triglycerides, total- and HDL-cholesterol levels; however, vitamin D supplementation increased HOMA-B.

scholarly journals Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Renfan Xu ◽  
Ke Yang ◽  
Sui Li ◽  
Meiyan Dai ◽  
Guangzhi Chen
Keyword(s):  
Publication Bias ◽  
Green Tea ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Tea Consumption ◽  
Randomized Controlled ◽  
Funnel Plots

Abstract Background Strong epidemiologic evidence indicates that green tea intake is protective against hyperlipidemia; however, randomized controlled studies have presented varying results. In the present study, we aimed to conduct a literature review and meta-analysis to assess the effect of green tea on blood lipids. Methods PubMed, Embase, and the Cochrane Library were electronically explored from inception to September 2019 for all relevant studies. Random effect models were used to estimate blood lipid changes between green tea supplementation and control groups by evaluating the weighted mean differences (WMD) with 95% confidence intervals (CIs). The risk of bias for study was assessed using the Cochrane tool. Publication bias was evaluated using funnel plots and Egger’s tests. Results Thirty-one trials with a total of 3321 subjects were included in the meta-analysis. In general, green tea intake significantly lowered the total cholesterol (TC); WMD: − 4.66 mg/dL; 95% CI: − 6.36, − 2.96 mg/dL; P < 0.0001) and low-density lipoprotein (LDL) cholesterol (WMD:− 4.55 mg/dL; 95% CI: − 6.31, − 2.80 mg/dL; P < 0.0001) levels compared with those in the control. Green tea consumption did not affect high-density lipoprotein (HDL) cholesterol; however, it reduced the triglycerides compared with that in the control (WMD: − 3.77 mg/dL; 95% CI: − 8.90, 1.37 mg/dL; P = 0.15). In addition, significant publication bias from funnel plots or Egger’s tests was not evident. Conclusions Collectively, consumption of green tea lowers LDL cholesterol and TC, but not HDL cholesterol or triglycerides in both normal weight subjects and those who were overweight/obese; however, additional well-designed studies that include more diverse populations and longer duration are warranted.

Differential effects of medium- and long-chain saturated fatty acids on blood lipid profile: a systematic review and meta-analysis

2018 ◽  
Vol 108 (4) ◽  
pp. 675-687 ◽  
Author(s):  
Nisha Panth ◽  
Kylie A Abbott ◽  
Cintia B Dias ◽  
Katie Wynne ◽  
Manohar L Garg
Keyword(s):  
Fatty Acids ◽  
Blood Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Saturated Fatty Acids ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Weighted Mean ◽  
Lipids And Lipoproteins ◽  
Long Chain

Abstract Background Medium-chain saturated fatty acids (MCFAs) may affect circulating lipids and lipoproteins differently than long-chain saturated fatty acids (LCSFAs), but the results from human intervention trials have been equivocal. Objective The aim of this study was to determine whether MCFAs and LCSFAs have differential impacts on blood lipids and lipoproteins. Design Five databases were searched (EMBASE, MEDLINE, CINAHL, Cochrane, and Scopus) until April 2018, and published clinical trials investigating the differential effects of dietary MCFAs and LCSFAs on blood lipids were included. Searches were limited to the English language and to studies with adults aged >18 y. Where possible, studies were pooled for meta-analysis using RevMan 5.2. The principle summary measure was the mean difference between groups calculated using the random-effects model. Results Eleven eligible crossover and 1 parallel trial were identified with a total of 299 participants [weighted mean ± SD age: 38 ± 3 y; weighted mean ± SD body mass index (kg/m2): 24 ± 2]. All studies were pooled for the meta-analysis. Diets enriched with MCFAs led to significantly higher high-density lipoprotein (HDL) cholesterol concentrations than diets enriched with LCSFAs (0.11 mmol/L; 95% CI: 0.07, 0.15 mmol/L) with no effect on triglyceride, low-density lipoprotein (LDL) cholesterol, and total cholesterol concentrations. Consumption of diets rich in MCFAs significantly increased apolipoprotein A-I (apoA-I) concentrations compared with diets rich in LCSFAs (0.08 g/L; 95% CI: 0.02, 0.14 g/L). There was no evidence of statistical heterogeneity for HDL cholesterol, apoA-I, and triglyceride concentrations; however, significant heterogeneity was observed for the total cholesterol (I2 = 49%) and LDL cholesterol analysis (I2 = 58%). Conclusion The findings of this research demonstrate a differential effect of MCFAs and LCSFAs on HDL cholesterol concentrations. Further investigations are warranted to elucidate the mechanism by which the lipid profile is altered. This trial was registered at www.crd.york.ac.uk/PROSPERO as CRD42017078277.

Effects of diacerein intake on cardiometabolic profiles in type 2 diabetics: a systematic review and meta-analysis of clinical trials.

2020 ◽  
Vol 27 ◽  
Author(s):  
Peyman Nowrouzi-Sohrabi ◽  
Reza Tabrizi ◽  
Mohammad Jalali ◽  
Navid Jamali ◽  
Shahla Rezaei ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Body Weight ◽  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Cochrane Central Register ◽  
Statistical Heterogeneity

Introduction: A systematic review and meta-analysis of clinical trials was undertaken to evaluate the effect of diacerein intake on cardiometabolic profiles in patients with type 2 diabetes mellitus (T2DM). Methods: Electronic databases such as PubMed, EMBASE, Scopus, Web of Science, Google Scholar, and Cochrane Central Register of Controlled Trials were searched from inception to 31 July 2019. Statistical heterogeneity was evaluated using Cochran’s Q test and I-square (I2 ) statistic. Data were pooled using random-effect models and weighted mean difference (WMD). Results: From 1,733 citations, seven clinical trials were eligible for inclusion and meta-analysis. A significant reduction in hemoglobin A1c (HbA1c) (WMD -0.73; 95%CI -1.25 to -0.21; P= 0.006; I2 = 72.2%) and body mass index (BMI) (WMD -0.55; 95%CI -1.03 to -0.07; P= 0.026; I2 = 9.5%) were identified. However, no significant effect of diacerein intake was identified on fasting blood sugar (FBS) (WMD - 9.00; 95%CI -22.57 to 4.57; P= 0.194; I2 = 60.5%), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD 0.39; 95%CI 0.95 to 1.73; P= 0.569; I2 = 2.2%), body weight (WMD -0.54; 95%CI -1.10 to 0.02; P= 0.059), triglycerides (WMD -0.56; 95%CI -24.16 to 23.03; P= 0.963; I2 = 0.0%), total-cholesterol (WMD -0.21; 95%CI -12.19 to 11.78; P= 0.973; I2 = 0.0%), HDL-cholesterol (WMD -0.96; 95%CI -2.85 to 0.93; P= 0.321; I2 = 0.0%), and LDL-cholesterol levels (WMD -0.09; 95%CI -8.43 to 8.25; P= 0.983; I2 = 37.8%). Conclusion: Diacerein intake may reduce HbA1c and BMI; however, no evidence of effect was observed for FBS, HOMA-IR, body weight, triglycerides, total-cholesterol, HDL-cholesterol or LDL-cholesterol.

The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 25 (30) ◽  
pp. 3266-3281 ◽  
Author(s):  
Hadis Fathizadeh ◽  
Alireza Milajerdi ◽  
Željko Reiner ◽  
Fariba Kolahdooz ◽  
Maryam Chamani ◽  
...  
Keyword(s):  
Serum Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Health Conditions ◽  
Carnitine Supplementation ◽  
Randomized Controlled ◽  
Cholesterol Levels ◽  
Vldl Cholesterol ◽  
Subgroup Analyses

Background: The findings of trials investigating the effects of L-carnitine administration on serum lipids are inconsistent. This meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effects of L-carnitine intake on serum lipids in patients and healthy individuals. Methods: Two authors independently searched electronic databases including MEDLINE, EMBASE, Cochrane Library, Web of Science, PubMed and Google Scholar from 1990 until August 1, 2019, in order to find relevant RCTs. The quality of selected RCTs was evaluated using the Cochrane Collaboration risk of bias tool. Cochrane’s Q test and I-square (I2) statistic were used to determine the heterogeneity across included trials. Weight mean difference (SMD) and 95% CI between the two intervention groups were used to determine pooled effect sizes. Subgroup analyses were performed to evaluate the source of heterogeneity based on suspected variables such as, participant’s health conditions, age, dosage of L-carnitine, duration of study, sample size, and study location between primary RCTs. Results: Out of 3460 potential papers selected based on keywords search, 67 studies met the inclusion criteria and were eligible for the meta-analysis. The pooled results indicated that L-carnitine administration led to a significant decrease in triglycerides (WMD: -10.35; 95% CI: -16.43, -4.27), total cholesterol (WMD: -9.47; 95% CI: - 13.23, -5.70) and LDL-cholesterol (LDL-C) concentrations (WMD: -6.25; 95% CI: -9.30, -3.21), and a significant increase in HDL-cholesterol (HDL-C) levels (WMD: 1.39; 95% CI: 0.21, 2.57). L-carnitine supplementation did not influence VLDL-cholesterol concentrations. When we stratified studies for the predefined factors such as dosage, and age, no significant effects of the intervention on triglycerides, LDL-C, and HDL-C levels were found. Conclusion: This meta-analysis demonstrated that L-carnitine administration significantly reduced triglycerides, total cholesterol and LDL-cholesterol levels, and significantly increased HDL-cholesterol levels in the pooled analyses, but did not affect VLDL-cholesterol levels; however, these findings were not confirmed in our subgroup analyses by participant’s health conditions, age, dosage of L-carnitine, duration of study, sample size, and study location.

Sign in / Sign up

Export Citation Format

Share Document